The amended dosing regimen was approved based on results from a post hoc analysis of the phase 2 MagnetisMM-3 trial.

Anselamimab is an anti-fibril monoclonal antibody designed to reduce or eliminate amyloid deposits by binding with targets of amino acids on misfolded amyloid fibrils.

Nostrum Labs is recalling all lots within expiry of Sucralfate Tablets 1g as the Company has shut down operations at its US sites and is unable to assure the quality of the product.

HealthDay News — About 90% of the ice cream sold in the US will no longer contain artificial dyes by 2028, federal health officials announced.

This new color is part of a bigger push to phase out artificial dyes, which have raised concerns in recent years.

Fifteen of 20 HLA-matched living donor recipients achieved the primary end point of being immunosuppression-free for more than 2 years.

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.

HealthDay News — Approved label populations for new drugs are broader than trial populations overall, according to a study published online July 8 in the Annals of Internal Medicine.

For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

No significantly increased risks observed for autoimmune disorder, atopic or allergic disorder, neurodevelopmental disorder.